FINWIRES · TerminalLIVE
FINWIRES

Elixir Energy Holds Largest Net Acreage in Queensland's Taroom Trough After 24% Increase in Discovered Resources, Euroz Hartleys Says

By

Elixir Energy (ASX:EXR) now holds an estimated contingent resource position of 3.5 trillion cubic feet equivalent (Tcfe) of gas in the Taroom Trough acreage following a 24% increase in discovered resources, giving it the largest net acreage position in the Queensland oil and gas basin, Euroz Hartleys said in an April 24 note.

That compares with a basin position of 1.7 Tcfe for peer Omega Oil & Gas (ASX:OMA), the equity research firm said.

Elixir Energy's Lorelle-3H well is arguably "the best drilled in the basin to date," with a horizontal length of 1,157 meters and average porosity of over 11%, which materially de-risks the company's upcoming hydraulic fracturing and flow test from the middle of June, Euroz Hartleys said.

The company also has a 50% stake in the Diona well, a side project on the fringes of the Taroom Trough that recently returned "encouraging" drilling results to prove potential opportunity for near-term cashflow, the equity research firm said.

Euroz Hartleys reiterated its speculative buy recommendation on Elixir Energy with an under-review price target of AU$0.28.

Elixir Energy and Omega Oil & Gas' shares each fell past 3% in recent Monday trade.

Related Articles

Asia

Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%

Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.

KOSDAQ:440110
Asia

ASX Biggest Losers

Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07

ASX 200ASX:COHASX:EVTASX:NXGASX:ORGASX:PDNASX:RHCASX:SX2ASX:TLXASX:TUAASX:WTC
Asia

Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal

Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.

BOM:524715NSE:SUNPHARMA